Document is current

Any future updates will be listed below

Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors

Crossref DOI link: https://doi.org/10.1007/s12149-025-02044-5

Published Online: 2025-04-05

Published Print: 2025-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark